advertisement

List of abstracts related to

Listed by Classification

11.14 Investigational drugs; pharmacological experiments (2508 abstracts found)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Olander KW
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Ha A
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Naik M
Clinical Ophthalmology 2021; 15: 2683-2692 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Sakata R
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Kapur M
Clinical Ophthalmology 2021; 15: 2683-2692 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Sato MA
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Fujishiro T
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Kim YK
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Saito H
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Abrams MA
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Jeoung JW
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Gupta V; Sethi H
Clinical Ophthalmology 2021; 15: 2683-2692 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Nakamura N
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Satyal S
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Jerkins GW
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Kim J
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Honjo M
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Srivastava K
Clinical Ophthalmology 2021; 15: 2683-2692 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Lu F; Dinh P
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Kim S
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Shirato S; Miyamoto E
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Park KH
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Odani-Kawabata N; Chabi A
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Yamada Y; Aihara M
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Shams NK
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

92720 Netarsudil-related Eyelid Wound Dehiscence
Kim HM
Journal of Glaucoma 2021; 30: 206-208 (IGR: 22-1)

92303 The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment
Rozpędek-Kamińska W
International journal of molecular sciences 2021; 22: (IGR: 22-1)

92360 Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma
Vallée A
Biomedicines 2021; 9: (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Tan C
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Li G
eLife 2021; 10: (IGR: 22-1)

92310 Antiglaucoma Potential of β-Glucogallin Is Mediated by Modulating Mitochondrial Responses in Experimentally Induced Glaucoma
Cao T
Neuroimmunomodulation 2021; 0: 1-10 (IGR: 22-1)

92476 Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension
Roddy GW
Current Eye Research 2021; 0: 1-6 (IGR: 22-1)

92635 Rhopressa-induced corneal edema: a case report
Chu MJ
Journal of Medical Case Reports 2021; 15: 182 (IGR: 22-1)

92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Araie M
Advances in Therapy 2021; 38: 1757-1775 (IGR: 22-1)

92784 The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery
Fujimoto H
Translational vision science & technology 2021; 10: 18 (IGR: 22-1)

92168 New considerations for the clinical efficacy of old and new topical glaucoma medications
MacIver S
Clinical and Experimental Optometry 2021; 104: 350-366 (IGR: 22-1)

92055 Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma
Al-Humimat G
Journal of experimental pharmacology 2021; 13: 197-212 (IGR: 22-1)

92762 Effectiveness and Tolerability of Netarsudil in Combination with Other Ocular Hypotensive Agents
Prager AJ
Ophthalmology. Glaucoma 2021; 4: 597-603 (IGR: 22-1)

92458 MiR-137 promotes cell growth and inhibits extracellular matrix protein expression in HO-induced human trabecular meshwork cells by targeting Src
Wang L
Neuroscience Letters 2021; 755: 135902 (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
van der Merwe Y
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Mehta AA
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92335 Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy
Riva I
European Journal of Ophthalmology 2021; 0: 1120672121999344 (IGR: 22-1)

92695 Responsiveness to ripasudil may be a potential outcome marker for selective laser trabeculoplasty in patients with primary open-angle glaucoma
Baba T
Scientific reports 2021; 11: 5812 (IGR: 22-1)

92570 A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
Zaman F
Current Medical Research and Opinion 2021; 37: 1011-1020 (IGR: 22-1)

92580 Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma
Amankwa CE
Antioxidants (Basel, Switzerland) 2021; 10: (IGR: 22-1)

92360 Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma
Vallée A
Biomedicines 2021; 9: (IGR: 22-1)

92662 Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension
Batra M
European Journal of Ophthalmology 2021; 0: 11206721211008783 (IGR: 22-1)

92055 Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma
Marashdeh I
Journal of experimental pharmacology 2021; 13: 197-212 (IGR: 22-1)

92695 Responsiveness to ripasudil may be a potential outcome marker for selective laser trabeculoplasty in patients with primary open-angle glaucoma
Hirooka K
Scientific reports 2021; 11: 5812 (IGR: 22-1)

92310 Antiglaucoma Potential of β-Glucogallin Is Mediated by Modulating Mitochondrial Responses in Experimentally Induced Glaucoma
Wang J
Neuroimmunomodulation 2021; 0: 1-10 (IGR: 22-1)

92335 Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy
Micheletti E
European Journal of Ophthalmology 2021; 0: 1120672121999344 (IGR: 22-1)

92662 Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension
Gupta S
European Journal of Ophthalmology 2021; 0: 11206721211008783 (IGR: 22-1)

92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Sugiyama K
Advances in Therapy 2021; 38: 1757-1775 (IGR: 22-1)

92784 The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery
Setoguchi Y
Translational vision science & technology 2021; 10: 18 (IGR: 22-1)

92303 The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment
Galita G
International journal of molecular sciences 2021; 22: (IGR: 22-1)

92635 Rhopressa-induced corneal edema: a case report
Song M
Journal of Medical Case Reports 2021; 15: 182 (IGR: 22-1)

92580 Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma
Gondi SR
Antioxidants (Basel, Switzerland) 2021; 10: (IGR: 22-1)

92360 Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma
Vallée JN
Biomedicines 2021; 9: (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Lee C
eLife 2021; 10: (IGR: 22-1)

92720 Netarsudil-related Eyelid Wound Dehiscence
Tran AQ
Journal of Glaucoma 2021; 30: 206-208 (IGR: 22-1)

92570 A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
Gieser SC
Current Medical Research and Opinion 2021; 37: 1011-1020 (IGR: 22-1)

92360 Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma
Vallée JN
Biomedicines 2021; 9: (IGR: 22-1)

92458 MiR-137 promotes cell growth and inhibits extracellular matrix protein expression in HO-induced human trabecular meshwork cells by targeting Src
Tian Y
Neuroscience Letters 2021; 755: 135902 (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Kanu LN
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92335 Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy
Micheletti E
European Journal of Ophthalmology 2021; 0: 1120672121999344 (IGR: 22-1)

92762 Effectiveness and Tolerability of Netarsudil in Combination with Other Ocular Hypotensive Agents
Tang M
Ophthalmology. Glaucoma 2021; 4: 597-603 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Jia F
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92476 Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension
Chowdhury UR
Current Eye Research 2021; 0: 1-6 (IGR: 22-1)

92168 New considerations for the clinical efficacy of old and new topical glaucoma medications
Stout N
Clinical and Experimental Optometry 2021; 104: 350-366 (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Murphy MC
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92580 Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma
Dibas A
Antioxidants (Basel, Switzerland) 2021; 10: (IGR: 22-1)

92335 Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy
Fausto R
European Journal of Ophthalmology 2021; 0: 1120672121999344 (IGR: 22-1)

92762 Effectiveness and Tolerability of Netarsudil in Combination with Other Ocular Hypotensive Agents
Pleet AL
Ophthalmology. Glaucoma 2021; 4: 597-603 (IGR: 22-1)

92662 Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension
Nair AB
European Journal of Ophthalmology 2021; 0: 11206721211008783 (IGR: 22-1)

92168 New considerations for the clinical efficacy of old and new topical glaucoma medications
Ricci O
Clinical and Experimental Optometry 2021; 104: 350-366 (IGR: 22-1)

92720 Netarsudil-related Eyelid Wound Dehiscence
Yang C
Journal of Glaucoma 2021; 30: 206-208 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Zhang P
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92055 Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma
Daradkeh D
Journal of experimental pharmacology 2021; 13: 197-212 (IGR: 22-1)

92458 MiR-137 promotes cell growth and inhibits extracellular matrix protein expression in HO-induced human trabecular meshwork cells by targeting Src
Cao Y
Neuroscience Letters 2021; 755: 135902 (IGR: 22-1)

92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Aso K
Advances in Therapy 2021; 38: 1757-1775 (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Sims JR
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92570 A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
Schwartz GF
Current Medical Research and Opinion 2021; 37: 1011-1020 (IGR: 22-1)

92360 Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma
Lecarpentier Y
Biomedicines 2021; 9: (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Read AT
eLife 2021; 10: (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Sood-Mendiratta S
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92310 Antiglaucoma Potential of β-Glucogallin Is Mediated by Modulating Mitochondrial Responses in Experimentally Induced Glaucoma
Wu Y
Neuroimmunomodulation 2021; 0: 1-10 (IGR: 22-1)

92695 Responsiveness to ripasudil may be a potential outcome marker for selective laser trabeculoplasty in patients with primary open-angle glaucoma
Nii H
Scientific reports 2021; 11: 5812 (IGR: 22-1)

92476 Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension
Monson KJ
Current Eye Research 2021; 0: 1-6 (IGR: 22-1)

92303 The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment
Siwecka N
International journal of molecular sciences 2021; 22: (IGR: 22-1)

92360 Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma
Lecarpentier Y
Biomedicines 2021; 9: (IGR: 22-1)

92635 Rhopressa-induced corneal edema: a case report
Palmares T
Journal of Medical Case Reports 2021; 15: 182 (IGR: 22-1)

92784 The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery
Kiryu J
Translational vision science & technology 2021; 10: 18 (IGR: 22-1)

92635 Rhopressa-induced corneal edema: a case report
Song A
Journal of Medical Case Reports 2021; 15: 182 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Sun X
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Kanemoto K
Advances in Therapy 2021; 38: 1757-1775 (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Faiq MA
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Quinones R
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92476 Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension
Fautsch MP
Current Eye Research 2021; 0: 1-6 (IGR: 22-1)

92570 A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
Swan C
Current Medical Research and Opinion 2021; 37: 1011-1020 (IGR: 22-1)

92695 Responsiveness to ripasudil may be a potential outcome marker for selective laser trabeculoplasty in patients with primary open-angle glaucoma
Kiuchi Y
Scientific reports 2021; 11: 5812 (IGR: 22-1)

92762 Effectiveness and Tolerability of Netarsudil in Combination with Other Ocular Hypotensive Agents
Petito LC
Ophthalmology. Glaucoma 2021; 4: 597-603 (IGR: 22-1)

92310 Antiglaucoma Potential of β-Glucogallin Is Mediated by Modulating Mitochondrial Responses in Experimentally Induced Glaucoma
Wang L
Neuroimmunomodulation 2021; 0: 1-10 (IGR: 22-1)

92335 Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy
Bruttini C
European Journal of Ophthalmology 2021; 0: 1120672121999344 (IGR: 22-1)

92458 MiR-137 promotes cell growth and inhibits extracellular matrix protein expression in HO-induced human trabecular meshwork cells by targeting Src
Ma Q
Neuroscience Letters 2021; 755: 135902 (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Wang K
eLife 2021; 10: (IGR: 22-1)

92662 Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension
Dhanawat M
European Journal of Ophthalmology 2021; 0: 11206721211008783 (IGR: 22-1)

92720 Netarsudil-related Eyelid Wound Dehiscence
Dagi Glass LR
Journal of Glaucoma 2021; 30: 206-208 (IGR: 22-1)

92303 The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment
Carroll SL
International journal of molecular sciences 2021; 22: (IGR: 22-1)

92580 Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma
Weston C
Antioxidants (Basel, Switzerland) 2021; 10: (IGR: 22-1)

92055 Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma
Kooner K
Journal of experimental pharmacology 2021; 13: 197-212 (IGR: 22-1)

92458 MiR-137 promotes cell growth and inhibits extracellular matrix protein expression in HO-induced human trabecular meshwork cells by targeting Src
Zhao S
Neuroscience Letters 2021; 755: 135902 (IGR: 22-1)

92570 A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
Williams JM
Current Medical Research and Opinion 2021; 37: 1011-1020 (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Ha J
eLife 2021; 10: (IGR: 22-1)

92762 Effectiveness and Tolerability of Netarsudil in Combination with Other Ocular Hypotensive Agents
Tanna AP
Ophthalmology. Glaucoma 2021; 4: 597-603 (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Yang XL
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Hawkins A
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Qiao Y
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92303 The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment
Diehl JA
International journal of molecular sciences 2021; 22: (IGR: 22-1)

92635 Rhopressa-induced corneal edema: a case report
Song J
Journal of Medical Case Reports 2021; 15: 182 (IGR: 22-1)

92335 Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy
De Angelis G
European Journal of Ophthalmology 2021; 0: 1120672121999344 (IGR: 22-1)

92580 Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma
Funk A
Antioxidants (Basel, Switzerland) 2021; 10: (IGR: 22-1)

92662 Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension
Sandal S
European Journal of Ophthalmology 2021; 0: 11206721211008783 (IGR: 22-1)

92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Kothapalli K
Advances in Therapy 2021; 38: 1757-1775 (IGR: 22-1)

92310 Antiglaucoma Potential of β-Glucogallin Is Mediated by Modulating Mitochondrial Responses in Experimentally Induced Glaucoma
Zhang H
Neuroimmunomodulation 2021; 0: 1-10 (IGR: 22-1)

92335 Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy
Ceccuzzi R
European Journal of Ophthalmology 2021; 0: 1120672121999344 (IGR: 22-1)

92662 Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension
Morsy MA
European Journal of Ophthalmology 2021; 0: 11206721211008783 (IGR: 22-1)

92580 Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma
Nguyen T
Antioxidants (Basel, Switzerland) 2021; 10: (IGR: 22-1)

92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Kopczynski C
Advances in Therapy 2021; 38: 1757-1775 (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Ho LC
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Chen X
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Kuhn M
eLife 2021; 10: (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Lehrer RA
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92303 The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment
Kucharska E
International journal of molecular sciences 2021; 22: (IGR: 22-1)

92580 Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma
Nguyen KT
Antioxidants (Basel, Switzerland) 2021; 10: (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Navarro I
eLife 2021; 10: (IGR: 22-1)

92303 The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment
Pytel D
International journal of molecular sciences 2021; 22: (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Conner IP
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Wang Y
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Senchyna M
Advances in Therapy 2021; 38: 1757-1775 (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Malhotra K
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92335 Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy
Quaranta L
European Journal of Ophthalmology 2021; 0: 1120672121999344 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Chen J
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92580 Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma
Ellis DZ
Antioxidants (Basel, Switzerland) 2021; 10: (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Yu Y
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92303 The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment
Majsterek I
International journal of molecular sciences 2021; 22: (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Papas R
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Hollander DA
Advances in Therapy 2021; 38: 1757-1775 (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Cui J
eLife 2021; 10: (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Hillman D
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Leung CK
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Young K
eLife 2021; 10: (IGR: 22-1)

92580 Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma
Acharya S
Antioxidants (Basel, Switzerland) 2021; 10: (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Lei Y
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Wollstein G
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Gorijavolu R
eLife 2021; 10: (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Wilensky JT; Aref AA
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Sulchek T
eLife 2021; 10: (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Schuman JS
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Vajaranant TS
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Kopczynski C
eLife 2021; 10: (IGR: 22-1)

92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
Chan KC
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0: (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Farsiu S
eLife 2021; 10: (IGR: 22-1)

92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Edward DP
European Journal of Ophthalmology 2021; 0: 1120672121998913 (IGR: 22-1)

92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Samples J; Challa P; Ethier CR; Stamer WD
eLife 2021; 10: (IGR: 22-1)

91635 Netarsudil for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Literature Review
Gonzalez LE
Annals of Pharmacotherapy 2020; 0: 1060028020971215 (IGR: 21-4)

91117 Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
Wang Y
Clinics 2020; 75: e1874 (IGR: 21-4)

91371 Trabodenoson on trabecular meshwork rejuvenation: a comprehensive review of clinical data
Qiu TG
Expert Opinion on Investigational Drugs 2021; 30: 227-236 (IGR: 21-4)

91467 A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma
Peace JH
Ophthalmology and therapy 2021; 10: 89-100 (IGR: 21-4)

91775 Effect of Rho Kinase Inhibitor Ripasudil (K-115) on Isolated Porcine Retinal Arterioles
Kamiya T
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 104-111 (IGR: 21-4)

91292 Reticular Epithelial Edema: An Uncommon Side Effect of ROCK/NET Inhibitor Netarsudil
Chen H
Journal of Glaucoma 2020; 29: e124-e126 (IGR: 21-4)

91403 Intraocular pressure-lowering effect of mycelia extract in a glaucoma rat model
Horng CT
International journal of medical sciences 2021; 18: 1007-1014 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Lorenzo-Soler L
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91674 Rho kinase inhibitors as new local therapy option in primary open angle glaucoma
Erb C
Ophthalmologe 2021; 118: 449-460 (IGR: 21-4)

91050 The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma
Jayanetti V
Journal of experimental pharmacology 2020; 12: 539-548 (IGR: 21-4)

91831 Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
Harasymowycz P
British Journal of Ophthalmology 2022; 106: 640-647 (IGR: 21-4)

91410 Cannabinoids in Glaucoma Patients: The Never-Ending Story
Passani A
Journal of clinical medicine 2020; 9: (IGR: 21-4)

91664 Effects of Ripasudil on Open-Angle Glaucoma after Circumferential Suture Trabeculotomy Ab Interno
Sato T
Journal of clinical medicine 2021; 10: (IGR: 21-4)

91192 Intraocular pressure-lowering effects of ripasudil, a rho-kinase inhibitor, and selective laser trabeculoplasty as adjuvant therapy in patients with uncontrolled glaucoma
Ono K
International Ophthalmology 2021; 41: 605-611 (IGR: 21-4)

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Singh IP
Journal of Glaucoma 2020; 29: 878-884 (IGR: 21-4)

91857 Neuroprotective effect of the somatostatin receptor 5 agonist L-817,818 on retinal ganglion cells in experimental glaucoma
Zhang Y
Experimental Eye Research 2021; 204: 108449 (IGR: 21-4)

91788 Effects of French maritime pine bark/bilberry fruit extracts on intraocular pressure for primary open-angle glaucoma
Manabe K
Journal of clinical biochemistry and nutrition 2021; 68: 67-72 (IGR: 21-4)

91139 ROCK inhibitors beneficially alter the spatial configuration of TGFβ2-treated 3D organoids from a human trabecular meshwork (HTM)
Ota C
Scientific reports 2020; 10: 20292 (IGR: 21-4)

91674 Rho kinase inhibitors as new local therapy option in primary open angle glaucoma
Konieczka K
Ophthalmologe 2021; 118: 449-460 (IGR: 21-4)

91192 Intraocular pressure-lowering effects of ripasudil, a rho-kinase inhibitor, and selective laser trabeculoplasty as adjuvant therapy in patients with uncontrolled glaucoma
Sakemi F
International Ophthalmology 2021; 41: 605-611 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Olafsdottir OB
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91410 Cannabinoids in Glaucoma Patients: The Never-Ending Story
Posarelli C
Journal of clinical medicine 2020; 9: (IGR: 21-4)

91857 Neuroprotective effect of the somatostatin receptor 5 agonist L-817,818 on retinal ganglion cells in experimental glaucoma
Wu N
Experimental Eye Research 2021; 204: 108449 (IGR: 21-4)

91635 Netarsudil for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Literature Review
Boylan PM
Annals of Pharmacotherapy 2020; 0: 1060028020971215 (IGR: 21-4)

91139 ROCK inhibitors beneficially alter the spatial configuration of TGFβ2-treated 3D organoids from a human trabecular meshwork (HTM)
Ida Y
Scientific reports 2020; 10: 20292 (IGR: 21-4)

91292 Reticular Epithelial Edema: An Uncommon Side Effect of ROCK/NET Inhibitor Netarsudil
McMillin JC
Journal of Glaucoma 2020; 29: e124-e126 (IGR: 21-4)

91403 Intraocular pressure-lowering effect of mycelia extract in a glaucoma rat model
Yang YL
International journal of medical sciences 2021; 18: 1007-1014 (IGR: 21-4)

91788 Effects of French maritime pine bark/bilberry fruit extracts on intraocular pressure for primary open-angle glaucoma
Kaidzu S
Journal of clinical biochemistry and nutrition 2021; 68: 67-72 (IGR: 21-4)

91831 Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
Royer C
British Journal of Ophthalmology 2022; 106: 640-647 (IGR: 21-4)

91467 A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma
McKee HJ
Ophthalmology and therapy 2021; 10: 89-100 (IGR: 21-4)

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Fechtner RD
Journal of Glaucoma 2020; 29: 878-884 (IGR: 21-4)

91775 Effect of Rho Kinase Inhibitor Ripasudil (K-115) on Isolated Porcine Retinal Arterioles
Omae T
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 104-111 (IGR: 21-4)

91117 Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
Liao Y
Clinics 2020; 75: e1874 (IGR: 21-4)

91664 Effects of Ripasudil on Open-Angle Glaucoma after Circumferential Suture Trabeculotomy Ab Interno
Kawaji T
Journal of clinical medicine 2021; 10: (IGR: 21-4)

91050 The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma
Sandhu S
Journal of experimental pharmacology 2020; 12: 539-548 (IGR: 21-4)

91410 Cannabinoids in Glaucoma Patients: The Never-Ending Story
Sframeli AT
Journal of clinical medicine 2020; 9: (IGR: 21-4)

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Myers JS
Journal of Glaucoma 2020; 29: 878-884 (IGR: 21-4)

91788 Effects of French maritime pine bark/bilberry fruit extracts on intraocular pressure for primary open-angle glaucoma
Tsutsui A
Journal of clinical biochemistry and nutrition 2021; 68: 67-72 (IGR: 21-4)

91139 ROCK inhibitors beneficially alter the spatial configuration of TGFβ2-treated 3D organoids from a human trabecular meshwork (HTM)
Ohguro H
Scientific reports 2020; 10: 20292 (IGR: 21-4)

91831 Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
Cui AX
British Journal of Ophthalmology 2022; 106: 640-647 (IGR: 21-4)

91117 Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
Nie X
Clinics 2020; 75: e1874 (IGR: 21-4)

91192 Intraocular pressure-lowering effects of ripasudil, a rho-kinase inhibitor, and selective laser trabeculoplasty as adjuvant therapy in patients with uncontrolled glaucoma
Marumoto T
International Ophthalmology 2021; 41: 605-611 (IGR: 21-4)

91403 Intraocular pressure-lowering effect of mycelia extract in a glaucoma rat model
Chen CC
International journal of medical sciences 2021; 18: 1007-1014 (IGR: 21-4)

91857 Neuroprotective effect of the somatostatin receptor 5 agonist L-817,818 on retinal ganglion cells in experimental glaucoma
Li Q
Experimental Eye Research 2021; 204: 108449 (IGR: 21-4)

91050 The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma
Lusthaus JA
Journal of experimental pharmacology 2020; 12: 539-548 (IGR: 21-4)

91788 Effects of French maritime pine bark/bilberry fruit extracts on intraocular pressure for primary open-angle glaucoma
Tsutsui A
Journal of clinical biochemistry and nutrition 2021; 68: 67-72 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Garhöfer G
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91467 A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma
Kopczynski CC
Ophthalmology and therapy 2021; 10: 89-100 (IGR: 21-4)

91775 Effect of Rho Kinase Inhibitor Ripasudil (K-115) on Isolated Porcine Retinal Arterioles
Nakabayashi S
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 104-111 (IGR: 21-4)

91292 Reticular Epithelial Edema: An Uncommon Side Effect of ROCK/NET Inhibitor Netarsudil
Frankfort BJ
Journal of Glaucoma 2020; 29: e124-e126 (IGR: 21-4)

91857 Neuroprotective effect of the somatostatin receptor 5 agonist L-817,818 on retinal ganglion cells in experimental glaucoma
Hu X
Experimental Eye Research 2021; 204: 108449 (IGR: 21-4)

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Kim T
Journal of Glaucoma 2020; 29: 878-884 (IGR: 21-4)

91788 Effects of French maritime pine bark/bilberry fruit extracts on intraocular pressure for primary open-angle glaucoma
Mochiji M
Journal of clinical biochemistry and nutrition 2021; 68: 67-72 (IGR: 21-4)

91410 Cannabinoids in Glaucoma Patients: The Never-Ending Story
Perciballi L
Journal of clinical medicine 2020; 9: (IGR: 21-4)

91139 ROCK inhibitors beneficially alter the spatial configuration of TGFβ2-treated 3D organoids from a human trabecular meshwork (HTM)
Hikage F
Scientific reports 2020; 10: 20292 (IGR: 21-4)

91292 Reticular Epithelial Edema: An Uncommon Side Effect of ROCK/NET Inhibitor Netarsudil
Al-Mohtaseb Z
Journal of Glaucoma 2020; 29: e124-e126 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Jansook P
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91403 Intraocular pressure-lowering effect of mycelia extract in a glaucoma rat model
Huang YS
International journal of medical sciences 2021; 18: 1007-1014 (IGR: 21-4)

91775 Effect of Rho Kinase Inhibitor Ripasudil (K-115) on Isolated Porcine Retinal Arterioles
Takahashi K
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 104-111 (IGR: 21-4)

91831 Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
Barbeau M
British Journal of Ophthalmology 2022; 106: 640-647 (IGR: 21-4)

91857 Neuroprotective effect of the somatostatin receptor 5 agonist L-817,818 on retinal ganglion cells in experimental glaucoma
Wang L
Experimental Eye Research 2021; 204: 108449 (IGR: 21-4)

91831 Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
Jobin-Gervais K
British Journal of Ophthalmology 2022; 106: 640-647 (IGR: 21-4)

91788 Effects of French maritime pine bark/bilberry fruit extracts on intraocular pressure for primary open-angle glaucoma
Matsuoka Y
Journal of clinical biochemistry and nutrition 2021; 68: 67-72 (IGR: 21-4)

91775 Effect of Rho Kinase Inhibitor Ripasudil (K-115) on Isolated Porcine Retinal Arterioles
Tanner A
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 104-111 (IGR: 21-4)

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Usner DW
Journal of Glaucoma 2020; 29: 878-884 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Kristinsdottir IM
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91410 Cannabinoids in Glaucoma Patients: The Never-Ending Story
Pellegrini M
Journal of clinical medicine 2020; 9: (IGR: 21-4)

91403 Intraocular pressure-lowering effect of mycelia extract in a glaucoma rat model
Chen C
International journal of medical sciences 2021; 18: 1007-1014 (IGR: 21-4)

91857 Neuroprotective effect of the somatostatin receptor 5 agonist L-817,818 on retinal ganglion cells in experimental glaucoma
Sun JG
Experimental Eye Research 2021; 204: 108449 (IGR: 21-4)

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
McKee H
Journal of Glaucoma 2020; 29: 878-884 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Tan A
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91775 Effect of Rho Kinase Inhibitor Ripasudil (K-115) on Isolated Porcine Retinal Arterioles
Yoshida A
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 104-111 (IGR: 21-4)

91788 Effects of French maritime pine bark/bilberry fruit extracts on intraocular pressure for primary open-angle glaucoma
Takagi Y
Journal of clinical biochemistry and nutrition 2021; 68: 67-72 (IGR: 21-4)

91831 Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
Mathurin K
British Journal of Ophthalmology 2022; 106: 640-647 (IGR: 21-4)

91410 Cannabinoids in Glaucoma Patients: The Never-Ending Story
Guidi G
Journal of clinical medicine 2020; 9: (IGR: 21-4)

91403 Intraocular pressure-lowering effect of mycelia extract in a glaucoma rat model
Chen FA
International journal of medical sciences 2021; 18: 1007-1014 (IGR: 21-4)

91410 Cannabinoids in Glaucoma Patients: The Never-Ending Story
Figus M
Journal of clinical medicine 2020; 9: (IGR: 21-4)

91831 Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
Lachaine J
British Journal of Ophthalmology 2022; 106: 640-647 (IGR: 21-4)

91857 Neuroprotective effect of the somatostatin receptor 5 agonist L-817,818 on retinal ganglion cells in experimental glaucoma
Wang Z
Experimental Eye Research 2021; 204: 108449 (IGR: 21-4)

91788 Effects of French maritime pine bark/bilberry fruit extracts on intraocular pressure for primary open-angle glaucoma
Miyamoto E
Journal of clinical biochemistry and nutrition 2021; 68: 67-72 (IGR: 21-4)

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Sheng H
Journal of Glaucoma 2020; 29: 878-884 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Loftsson T
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91788 Effects of French maritime pine bark/bilberry fruit extracts on intraocular pressure for primary open-angle glaucoma
Tanito M
Journal of clinical biochemistry and nutrition 2021; 68: 67-72 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Stefansson E
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Lewis RA
Journal of Glaucoma 2020; 29: 878-884 (IGR: 21-4)

91831 Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
Beauchemin C
British Journal of Ophthalmology 2022; 106: 640-647 (IGR: 21-4)

91857 Neuroprotective effect of the somatostatin receptor 5 agonist L-817,818 on retinal ganglion cells in experimental glaucoma
Sun XH
Experimental Eye Research 2021; 204: 108449 (IGR: 21-4)

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Heah T; Kopczynski CC
Journal of Glaucoma 2020; 29: 878-884 (IGR: 21-4)

89941 Current and new pharmacotherapeutic approaches for glaucoma
Shalaby WS
Expert Opinion in Pharmacotherapy 2020; 21: 2027-2040 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Cesar ALA
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90564 Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
Aihara M
Japanese Journal of Ophthalmology 2020; 64: 398-406 (IGR: 21-3)

90309 Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
Rossi GCM
Scientific reports 2020; 10: 10468 (IGR: 21-3)

89941 Current and new pharmacotherapeutic approaches for glaucoma
Shalaby WS
Expert Opinion in Pharmacotherapy 2020; 21: 2027-2040 (IGR: 21-3)

90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Rossetti L
Journal of Glaucoma 2020; 29: 513-520 (IGR: 21-3)

90747 Tissue plasminogen activator attenuates outflow facility reduction in mouse model of juvenile open angle glaucoma
Gindina S
Experimental Eye Research 2020; 199: 108179 (IGR: 21-3)

90673 AR12286 Alleviates TGF-β-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery
Cheng WS
Molecules 2020; 25: (IGR: 21-3)

89941 Current and new pharmacotherapeutic approaches for glaucoma
Shalaby WS
Expert Opinion in Pharmacotherapy 2020; 21: 2027-2040 (IGR: 21-3)

89975 A comprehensive map of disease networks and molecular drug discoveries for glaucoma
Wang H
Scientific reports 2020; 10: 9719 (IGR: 21-3)

90210 Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study
Aihara M
American Journal of Ophthalmology 2020; 220: 53-63 (IGR: 21-3)

90673 AR12286 Alleviates TGF-β-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery
Chen CL
Molecules 2020; 25: (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Navarro LC
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90309 Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
Scudeller L
Scientific reports 2020; 10: 10468 (IGR: 21-3)

90210 Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study
Lu F
American Journal of Ophthalmology 2020; 220: 53-63 (IGR: 21-3)

90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Iester M
Journal of Glaucoma 2020; 29: 513-520 (IGR: 21-3)

90747 Tissue plasminogen activator attenuates outflow facility reduction in mouse model of juvenile open angle glaucoma
Hu Y
Experimental Eye Research 2020; 199: 108179 (IGR: 21-3)

90564 Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
Ropo A
Japanese Journal of Ophthalmology 2020; 64: 398-406 (IGR: 21-3)

89941 Current and new pharmacotherapeutic approaches for glaucoma
Shankar V
Expert Opinion in Pharmacotherapy 2020; 21: 2027-2040 (IGR: 21-3)

89975 A comprehensive map of disease networks and molecular drug discoveries for glaucoma
Deng Y
Scientific reports 2020; 10: 9719 (IGR: 21-3)

90747 Tissue plasminogen activator attenuates outflow facility reduction in mouse model of juvenile open angle glaucoma
Barron AO
Experimental Eye Research 2020; 199: 108179 (IGR: 21-3)

89941 Current and new pharmacotherapeutic approaches for glaucoma
Razeghinejad R
Expert Opinion in Pharmacotherapy 2020; 21: 2027-2040 (IGR: 21-3)

89975 A comprehensive map of disease networks and molecular drug discoveries for glaucoma
Wan L
Scientific reports 2020; 10: 9719 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Castilho RO
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90564 Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
Lu F
Japanese Journal of Ophthalmology 2020; 64: 398-406 (IGR: 21-3)

90673 AR12286 Alleviates TGF-β-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery
Chen JT
Molecules 2020; 25: (IGR: 21-3)

90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Tranchina L
Journal of Glaucoma 2020; 29: 513-520 (IGR: 21-3)

90210 Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study
Kawata H
American Journal of Ophthalmology 2020; 220: 53-63 (IGR: 21-3)

90309 Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
Lumini C
Scientific reports 2020; 10: 10468 (IGR: 21-3)

90210 Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study
Iwata A
American Journal of Ophthalmology 2020; 220: 53-63 (IGR: 21-3)

90309 Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
Bettio F
Scientific reports 2020; 10: 10468 (IGR: 21-3)

90673 AR12286 Alleviates TGF-β-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery
Lin LT
Molecules 2020; 25: (IGR: 21-3)

90564 Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
Kawata H
Japanese Journal of Ophthalmology 2020; 64: 398-406 (IGR: 21-3)

89941 Current and new pharmacotherapeutic approaches for glaucoma
Katz LJ
Expert Opinion in Pharmacotherapy 2020; 21: 2027-2040 (IGR: 21-3)

89975 A comprehensive map of disease networks and molecular drug discoveries for glaucoma
Huang L
Scientific reports 2020; 10: 9719 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Goulart GAC
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Ottobelli L
Journal of Glaucoma 2020; 29: 513-520 (IGR: 21-3)

90747 Tissue plasminogen activator attenuates outflow facility reduction in mouse model of juvenile open angle glaucoma
Qureshi Z; Danias J
Experimental Eye Research 2020; 199: 108179 (IGR: 21-3)

90564 Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
Iwata A
Japanese Journal of Ophthalmology 2020; 64: 398-406 (IGR: 21-3)

90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Coco G
Journal of Glaucoma 2020; 29: 513-520 (IGR: 21-3)

90210 Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study
Odani-Kawabata N
American Journal of Ophthalmology 2020; 220: 53-63 (IGR: 21-3)

90309 Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
Picasso E
Scientific reports 2020; 10: 10468 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Foureaux G
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90673 AR12286 Alleviates TGF-β-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery
Pao SI; Chen YH
Molecules 2020; 25: (IGR: 21-3)

90564 Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
Odani-Kawabata N
Japanese Journal of Ophthalmology 2020; 64: 398-406 (IGR: 21-3)

90309 Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
Ruberto G
Scientific reports 2020; 10: 10468 (IGR: 21-3)

90210 Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study
Shams NK
American Journal of Ophthalmology 2020; 220: 53-63 (IGR: 21-3)

90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Calcatelli E
Journal of Glaucoma 2020; 29: 513-520 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Ferreira AJ
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Ancona C
Journal of Glaucoma 2020; 29: 513-520 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Cronemberger S
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90309 Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
Briola A
Scientific reports 2020; 10: 10468 (IGR: 21-3)

90564 Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
Shams N
Japanese Journal of Ophthalmology 2020; 64: 398-406 (IGR: 21-3)

90673 AR12286 Alleviates TGF-β-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery
Lu DW
Molecules 2020; 25: (IGR: 21-3)

90309 Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
Mirabile A
Scientific reports 2020; 10: 10468 (IGR: 21-3)

90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Cirafici P; Cirafici P
Journal of Glaucoma 2020; 29: 513-520 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Gomes Faraco AA
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Manni G
Journal of Glaucoma 2020; 29: 513-520 (IGR: 21-3)

90309 Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
Paviglianiti A; Pasinetti GM; Bianchi PE
Scientific reports 2020; 10: 10468 (IGR: 21-3)

86454 Protection of the Retinal Ganglion Cells: Intravitreal Injection of Resveratrol in Mouse Model of Ocular Hypertension
Cao K
Investigative Ophthalmology and Visual Science 2020; 61: 13 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Roy Chowdhury U
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86454 Protection of the Retinal Ganglion Cells: Intravitreal Injection of Resveratrol in Mouse Model of Ocular Hypertension
Ishida T
Investigative Ophthalmology and Visual Science 2020; 61: 13 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Kudgus RA
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86454 Protection of the Retinal Ganglion Cells: Intravitreal Injection of Resveratrol in Mouse Model of Ocular Hypertension
Fang Y
Investigative Ophthalmology and Visual Science 2020; 61: 13 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Rinkoski TA; Holman BH
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86454 Protection of the Retinal Ganglion Cells: Intravitreal Injection of Resveratrol in Mouse Model of Ocular Hypertension
Shinohara K; Li X
Investigative Ophthalmology and Visual Science 2020; 61: 13 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Bahler CK; Hann CR
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86454 Protection of the Retinal Ganglion Cells: Intravitreal Injection of Resveratrol in Mouse Model of Ocular Hypertension
Nagaoka N
Investigative Ophthalmology and Visual Science 2020; 61: 13 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Reid JM
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86454 Protection of the Retinal Ganglion Cells: Intravitreal Injection of Resveratrol in Mouse Model of Ocular Hypertension
Ohno-Matsui K; Yoshida T
Investigative Ophthalmology and Visual Science 2020; 61: 13 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Dosa PI; Fautsch MP
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Nemoto E
International journal of molecular sciences 2019; 21: (IGR: 21-1)

85085 Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
Montero-Oleas N
BMC complementary medicine and therapies 2020; 20: 12 (IGR: 21-1)

84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Rocha LR
Aging Cell 2020; 19: e13089 (IGR: 21-1)

85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Wisely CE
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)

84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Ibrahim MM
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)

85228 Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
Chen W
Frontiers in pharmacology 2020; 11: 302 (IGR: 21-1)

84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Yamamoto K
Scientific reports 2019; 9: 19288 (IGR: 21-1)

85225 Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis
Park CW
EXCLI journal 2020; 19: 187-200 (IGR: 21-1)

85224 Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
Martin P
Clinical Ophthalmology 2020; 14: 885-896 (IGR: 21-1)

84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Tan J
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)

85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Sanz-González SM
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)

84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Caruso C
International Ophthalmology 2019; 0: (IGR: 21-1)

84489 New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Mehran NA
Eye 2020; 34: 72-88 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Yagi-Yaguchi Y
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Hommer N
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)

85112 Secondary Neuroprotection in Glaucoma Through the Concepts of Complementary Drug Therapy
Erb C
Klinische Monatsblätter für Augenheilkunde 2020; 237: 163-174 (IGR: 21-1)

84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Kokubun T
Scientific reports 2019; 9: 19288 (IGR: 21-1)

84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Wang X
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)

85085 Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
Arevalo-Rodriguez I
BMC complementary medicine and therapies 2020; 20: 12 (IGR: 21-1)

84489 New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Sinha S
Eye 2020; 34: 72-88 (IGR: 21-1)

84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Kojima S
International journal of molecular sciences 2019; 21: (IGR: 21-1)

85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Sheng H
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)

85228 Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
Yang X
Frontiers in pharmacology 2020; 11: 302 (IGR: 21-1)

85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Kallab M
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)

84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Nguyen Huu VA
Aging Cell 2020; 19: e13089 (IGR: 21-1)

85224 Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
Cohen A
Clinical Ophthalmology 2020; 14: 885-896 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Kojima T
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Maria DN
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)

85225 Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis
Han CT
EXCLI journal 2020; 19: 187-200 (IGR: 21-1)

85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Raga-Cervera J
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)

84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Pacente L
International Ophthalmology 2019; 0: (IGR: 21-1)

84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Sato K
Scientific reports 2019; 9: 19288 (IGR: 21-1)

84489 New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Razeghinejad R
Eye 2020; 34: 72-88 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Higa K
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Mishra SR
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)

85225 Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis
Sakaguchi Y
EXCLI journal 2020; 19: 187-200 (IGR: 21-1)

85224 Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
Uddin S
Clinical Ophthalmology 2020; 14: 885-896 (IGR: 21-1)

85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Aguirre Lipperheide M
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)

84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Palomino La Torre C
Aging Cell 2020; 19: e13089 (IGR: 21-1)

84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Troiano P
International Ophthalmology 2019; 0: (IGR: 21-1)

85228 Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
Fang J
Frontiers in pharmacology 2020; 11: 302 (IGR: 21-1)

84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Sugiyama T
International journal of molecular sciences 2019; 21: (IGR: 21-1)

85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Szegedi S
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)

85085 Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
Nuñez-González S
BMC complementary medicine and therapies 2020; 20: 12 (IGR: 21-1)

84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Cai S
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)

85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Heah T
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)

85225 Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis
Lee J
EXCLI journal 2020; 19: 187-200 (IGR: 21-1)

85228 Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
Zhang Y
Frontiers in pharmacology 2020; 11: 302 (IGR: 21-1)

84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
He F
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)

84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Akaishi T
Scientific reports 2019; 9: 19288 (IGR: 21-1)

84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Ostacolo C
International Ophthalmology 2019; 0: (IGR: 21-1)

85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Zanón-Moreno V
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)

85085 Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
Viteri-García A
BMC complementary medicine and therapies 2020; 20: 12 (IGR: 21-1)

85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Puchner S
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)

84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Guragain D
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)

84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Xu Q
Aging Cell 2020; 19: e13089 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Dogru M
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Kim T
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)

85224 Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
Epelbaum L
Clinical Ophthalmology 2020; 14: 885-896 (IGR: 21-1)

84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Jin D
International journal of molecular sciences 2019; 21: (IGR: 21-1)

85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Stjepanek K
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)

85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Chiner V
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)

85224 Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
Josiah S
Clinical Ophthalmology 2020; 14: 885-896 (IGR: 21-1)

84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Jabari M
Aging Cell 2020; 19: e13089 (IGR: 21-1)

85224 Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
Josiah S
Clinical Ophthalmology 2020; 14: 885-896 (IGR: 21-1)

84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Zhang D
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)

84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
D'Andrea L
International Ophthalmology 2019; 0: (IGR: 21-1)

85085 Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
Simancas-Racines D
BMC complementary medicine and therapies 2020; 20: 12 (IGR: 21-1)

84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Wang X
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Ibrahim OM
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Shimazaki A
Scientific reports 2019; 9: 19288 (IGR: 21-1)

84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Takai S
International journal of molecular sciences 2019; 21: (IGR: 21-1)

85228 Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
Zhu W
Frontiers in pharmacology 2020; 11: 302 (IGR: 21-1)

85225 Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis
Youn HY
EXCLI journal 2020; 19: 187-200 (IGR: 21-1)

84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Bartollino S
International Ophthalmology 2019; 0: (IGR: 21-1)

85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Bauer M
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)

84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Bartollino S
International Ophthalmology 2019; 0: (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Shimizu T
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Nakamura M
Scientific reports 2019; 9: 19288 (IGR: 21-1)

84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Maeda M
International journal of molecular sciences 2019; 21: (IGR: 21-1)

84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Li D
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)

85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Ramírez AI
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)

84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Krawczyk M
Aging Cell 2020; 19: e13089 (IGR: 21-1)

84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Jablonski MM
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)

85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Werkmeister RM
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)

84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Zhu X
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Tsubota K
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Kohmoto R
International journal of molecular sciences 2019; 21: (IGR: 21-1)

84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Shiga Y
Scientific reports 2019; 9: 19288 (IGR: 21-1)

85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Pinazo-Durán MD
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)

84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Weinreb RN
Aging Cell 2020; 19: e13089 (IGR: 21-1)

84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Costagliola C
International Ophthalmology 2019; 0: (IGR: 21-1)

84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Ueki M
International journal of molecular sciences 2019; 21: (IGR: 21-1)

84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Zhou L
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)

85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Schmetterer L
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)

84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Tsuda S
Scientific reports 2019; 9: 19288 (IGR: 21-1)

84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Skowronska-Krawczyk D
Aging Cell 2020; 19: e13089 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Shimazaki J
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Omodaka K
Scientific reports 2019; 9: 19288 (IGR: 21-1)

84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Oku H
International journal of molecular sciences 2019; 21: (IGR: 21-1)

85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Abensperg-Traun M
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)

84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Fan N; Liu X
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)

84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Ikeda T
International journal of molecular sciences 2019; 21: (IGR: 21-1)

85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Garhöfer G
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)

84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Saya H
Scientific reports 2019; 9: 19288 (IGR: 21-1)

85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Schmidl D
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)

84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Nakazawa T
Scientific reports 2019; 9: 19288 (IGR: 21-1)

82535 Rho-kinase inhibitors in the management of glaucoma
Berrino E
Expert Opinion on Therapeutic Patents 2019; 29: 817-827 (IGR: 20-4)

82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Guo Y
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)

82315 Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018)
Angeli A
Expert Opinion on Therapeutic Patents 2019; 29: 793-803 (IGR: 20-4)

82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Savinainen A
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)

82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Chițu I
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)

82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Heo JH
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)

82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Uchida T
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)

82614 Sustained scleral stiffening in rats after a single genipin treatment
Hannon BG
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)

82430 Latanoprost uptake and release from commercial contact lenses
Horne RR
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)

82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Ha JY
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)

82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Krishnan A
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)

82163 Novel therapies for glaucoma: a patent review (2013-2019)
Guglielmi P
Expert Opinion on Therapeutic Patents 2019; 29: 769-780 (IGR: 20-4)

82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Millar JC
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)

82222 Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
Sheppard JD
Clinical Ophthalmology 2019; 13: 1279-1288 (IGR: 20-4)

82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Fakhraie G
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)

82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Fernández-Albarral JA
International journal of molecular sciences 2019; 20: (IGR: 20-4)

82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Aihara M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)

82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Aillegas NA
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)

82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Choi KJ
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)

82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Sinha S
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)

82273 Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595
Bonardi A
Expert Opinion on Therapeutic Patents 2019; 29: 753-759 (IGR: 20-4)

82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)

82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Lanza M
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)

82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Savinainen A
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)

82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Quaranta L
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)

82239 Leucaena leucocephala (Lam.) galactomannan nanoparticles: Optimization and characterization for ocular delivery in glaucoma treatment
Mittal N
International Journal of Biological Macromolecules 2019; 139: 1252-1262 (IGR: 20-4)

82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Lee D
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)

82273 Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 753-759 (IGR: 20-4)

82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Lu F
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)

82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Na YJ
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)

82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Mirghorbani M
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)

82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Altamimi ASA
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)

82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Mehrabian Z
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)

82239 Leucaena leucocephala (Lam.) galactomannan nanoparticles: Optimization and characterization for ocular delivery in glaucoma treatment
Kaur G
International Journal of Biological Macromolecules 2019; 139: 1252-1262 (IGR: 20-4)

82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Savinainen A
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)

82535 Rho-kinase inhibitors in the management of glaucoma
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 817-827 (IGR: 20-4)

82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Rascati KL
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)

82315 Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018)
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 793-803 (IGR: 20-4)

82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Tártara LI
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)

82614 Sustained scleral stiffening in rats after a single genipin treatment
Schwaner SA
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)

82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Savinainen A
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)

82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Kocab AJ
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)

82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Sung MS
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)

82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Ramírez AI
International journal of molecular sciences 2019; 20: (IGR: 20-4)

82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Gironi Carnevale UA
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)

82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Ueta T
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)

82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Riva I
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)

82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Prusakiewicz JJ
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)

82430 Latanoprost uptake and release from commercial contact lenses
Rich JT
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)

82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Voinea LM
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)

82222 Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
Singh IP
Clinical Ophthalmology 2019; 13: 1279-1288 (IGR: 20-4)

82163 Novel therapies for glaucoma: a patent review (2013-2019)
Carradori S
Expert Opinion on Therapeutic Patents 2019; 29: 769-780 (IGR: 20-4)

82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Oswald J
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)

82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Katz LJ
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)

82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Josiah S
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)

82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Kolomeyer NN
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)

82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Caballero G
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)

82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Kawata H
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)

82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Mele L
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)

82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Jung WH
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)

82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
de Hoz R
International journal of molecular sciences 2019; 20: (IGR: 20-4)

82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Carta F
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)

82430 Latanoprost uptake and release from commercial contact lenses
Bradley MW
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)

82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Istrate S
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)

82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Zacks DN
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)

82163 Novel therapies for glaucoma: a patent review (2013-2019)
Campestre C
Expert Opinion on Therapeutic Patents 2019; 29: 769-780 (IGR: 20-4)

82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Johnson MA
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)

82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Wilson JP
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)

82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Biagioli E
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)

82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Josiah S
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)

82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Park SW
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)

82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Kolomeyer NN
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)

82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Honjo M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)

82614 Sustained scleral stiffening in rats after a single genipin treatment
Boazak EM
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)

82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
López-Villarín N
International journal of molecular sciences 2019; 20: (IGR: 20-4)

82163 Novel therapies for glaucoma: a patent review (2013-2019)
Poce G
Expert Opinion on Therapeutic Patents 2019; 29: 769-780 (IGR: 20-4)

82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Park SB
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)

82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Myers JS
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)

82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Vrapciu A
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)

82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Tanaka Y
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)

82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Albers DS
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)

82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Aihara M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)

82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Spencer E
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)

82614 Sustained scleral stiffening in rats after a single genipin treatment
Gerberich BG
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)

82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Pang IH
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)

82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Marshak-Rothstein A
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)

82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Lawson KA
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)

82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Mollazadeh A
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)

82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Bifani Sconocchia M
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)

82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Campana V
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)

82430 Latanoprost uptake and release from commercial contact lenses
Pitt WG
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)

82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Richards KM
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)

82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Gregory-Ksander M
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)

82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Allemandi DA
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)

82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Bartollino S
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)

82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Vahedian Z
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)

82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Rulli E
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)

82614 Sustained scleral stiffening in rats after a single genipin treatment
Winger EJ
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)

82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Razeghinejad R
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)

82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Salobrar-García E
International journal of molecular sciences 2019; 20: (IGR: 20-4)

82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Bartollino S
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)

82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Yamamura K
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)

82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Rich CC
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)

82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Ciuluvică RC
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)

82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Kang S
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)

82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Lou Z
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)

82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Costagliola C
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)

82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
López-Cuenca I
International journal of molecular sciences 2019; 20: (IGR: 20-4)

82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Zarei R
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)

82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Tudosescu R
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)

82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Poli D
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)

82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Nair R
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)

82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Palma SD
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)

82614 Sustained scleral stiffening in rats after a single genipin treatment
Prausnitz MR
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)

82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Cohen ML
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)

82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Nam HJ
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)

82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Odani-Kawabata N
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)

82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Baumgartner RA
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)

82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Shams NK
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)

82614 Sustained scleral stiffening in rats after a single genipin treatment
Ethier CR
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)

82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Legramandi L
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)

82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Rashidzadeh H
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)

82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Bernstein SL
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)

82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Ahn JH
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)

82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Licastro E
International journal of molecular sciences 2019; 20: (IGR: 20-4)

82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Eslami Y; Mohammadi M
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)

82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol

Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)

82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Josiah S
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)

82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Inarejos-García AM
International journal of molecular sciences 2019; 20: (IGR: 20-4)

82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Josiah S
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)

82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Kim KY
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)

82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Hamzeh N
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)

82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Almodóvar P
International journal of molecular sciences 2019; 20: (IGR: 20-4)

82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Masoomi A
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)

82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Pinazo-Durán MD; Ramírez JM; Salazar JJ
International journal of molecular sciences 2019; 20: (IGR: 20-4)

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Woodward DF
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)

80720 Causative glaucoma treatment: promising targets and delivery systems
Mietzner R
Drug Discovery Today 2019; 24: 1606-1613 (IGR: 20-3)

81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Coman IC
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)

81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Angel Aillegas N
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)

80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Aihara M
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)

80737 Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial
Fan KR
Acta Ophthalmologica 2019; 97: e827-e832 (IGR: 20-3)

80599 Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model
Ekicier Acar S
European Journal of Ophthalmology 2019; 0: 1120672119833271 (IGR: 20-3)

81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Al Hammoud M
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)

81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Tártara LI
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)

80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Lu F
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)

80737 Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial
Baskaran M
Acta Ophthalmologica 2019; 97: e827-e832 (IGR: 20-3)

80720 Causative glaucoma treatment: promising targets and delivery systems
Breunig M
Drug Discovery Today 2019; 24: 1606-1613 (IGR: 20-3)

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Wang JW
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)

80599 Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model
Sarıcaoğlu MS
European Journal of Ophthalmology 2019; 0: 1120672119833271 (IGR: 20-3)

80737 Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial
Nongpiur ME
Acta Ophthalmologica 2019; 97: e827-e832 (IGR: 20-3)

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Coleman RA
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)

80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Kawata H
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)

81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Caballero G
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)

80599 Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model
Çolak A
European Journal of Ophthalmology 2019; 0: 1120672119833271 (IGR: 20-3)

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Coleman RA
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)

81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Tudosescu R
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)

81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Campana V
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)

80599 Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model
Aktaş Z
European Journal of Ophthalmology 2019; 0: 1120672119833271 (IGR: 20-3)

81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Iancu R
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Woodrooffe AJ
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)

80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Iwata A
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)

80737 Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial
Htoon HM
Acta Ophthalmologica 2019; 97: e827-e832 (IGR: 20-3)

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Woodrooffe AJ; Clark KL
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)

80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Liu K
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)

80737 Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial
De Leon JMS
Acta Ophthalmologica 2019; 97: e827-e832 (IGR: 20-3)

81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Allemandi DA
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)

80599 Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model
Sepici Dinçel A
European Journal of Ophthalmology 2019; 0: 1120672119833271 (IGR: 20-3)

81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Barac C
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Clark KL
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)

81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Popa CA
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Stamer WD
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)

81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Palma SD
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)

80737 Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial
Perera SA
Acta Ophthalmologica 2019; 97: e827-e832 (IGR: 20-3)

80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Odani-Kawabata N
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Tao G
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)

80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Shams NK
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)

80737 Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial
Belkin M
Acta Ophthalmologica 2019; 97: e827-e832 (IGR: 20-3)

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Fan S
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)

80737 Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial
Aung T
Acta Ophthalmologica 2019; 97: e827-e832 (IGR: 20-3)

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Toris CB
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)

79393 Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval
Duggan S
Drugs 2018; 78: 1925-1929 (IGR: 20-2)

79787 Evidence on neuroprotective properties of coenzyme Q10 in the treatment of glaucoma
Martucci A
Neural Regeneration Research 2019; 14: 197-200 (IGR: 20-2)

79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Kang X
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)

79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Hu C
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)

79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Lin C
Eye 2019; 33: 777-784 (IGR: 20-2)

80056 Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension
Fingeret M
Clinical and Experimental Optometry 2019; 102: 541-550 (IGR: 20-2)

79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Kahook MY
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)

79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Dang Y
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)

79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Shen Y
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)

79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Wu F
Eye 2019; 33: 777-784 (IGR: 20-2)

80056 Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension
Gaddie IB
Clinical and Experimental Optometry 2019; 102: 541-550 (IGR: 20-2)

79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Serle JB
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)

79787 Evidence on neuroprotective properties of coenzyme Q10 in the treatment of glaucoma
Nucci C
Neural Regeneration Research 2019; 14: 197-200 (IGR: 20-2)

79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Wang C
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)

79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Sun J
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)

80056 Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension
Bloomenstein M
Clinical and Experimental Optometry 2019; 102: 541-550 (IGR: 20-2)

79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Shah P
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)

79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Zhang Y
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)

79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Zhao H
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)

79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Mah FS
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)

79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Zheng T
Eye 2019; 33: 777-784 (IGR: 20-2)

79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Chen J
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)

79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Wang X
Eye 2019; 33: 777-784 (IGR: 20-2)

79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Kim T
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)

79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Waxman S
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)

79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Wang Z; Guan W
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)

79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Loewen RT
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)

79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Lei Y
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)

79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Chen Y
Eye 2019; 33: 777-784 (IGR: 20-2)

79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Raizman MB
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)

79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Loewen NA
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)

79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Sun X
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)

79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Wu X
Eye 2019; 33: 777-784 (IGR: 20-2)

79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Ge R
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)

79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Heah T
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)

79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Wang R
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)

79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Deng Y
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)

79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Ramirez-Davis N; Kopczynski CC
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)

79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Tai X
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)

79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Usner DW; Novack GD;
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)

78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Moshirfar M
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)

79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Ashwinbalaji S
Scientific reports 2018; 8: 15472 (IGR: 20-1)

79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Pitha I
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)

79141 Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
Komizo T
Japanese Journal of Ophthalmology 2019; 63: 40-45 (IGR: 20-1)

78899 Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma
Matsou A
Expert Opinion on Investigational Drugs 2018; 27: 777-785 (IGR: 20-1)

78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Weinreb RN
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)

78351 Glaucoma Drugs in the Pipeline
Kaufman PL
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 345-351 (IGR: 20-1)

79132 Rho-kinase (ROCK) Inhibitors- A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Abbhi V
Current Medicinal Chemistry 2018; 0: (IGR: 20-1)

79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Senthilkumari S
Scientific reports 2018; 8: 15472 (IGR: 20-1)

78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Liebmann JM
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)

78351 Glaucoma Drugs in the Pipeline
Mohr ME
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 345-351 (IGR: 20-1)

79132 Rho-kinase (ROCK) Inhibitors- A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Piplani P
Current Medicinal Chemistry 2018; 0: (IGR: 20-1)

78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Parker L
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)

79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Oglesby E
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)

79141 Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
Ono T
Japanese Journal of Ophthalmology 2019; 63: 40-45 (IGR: 20-1)

78899 Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma
Anastasopoulos E
Expert Opinion on Investigational Drugs 2018; 27: 777-785 (IGR: 20-1)

79141 Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
Yagi A
Japanese Journal of Ophthalmology 2019; 63: 40-45 (IGR: 20-1)

78351 Glaucoma Drugs in the Pipeline
Riccomini SP
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 345-351 (IGR: 20-1)

79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Chow A
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)

79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Gowripriya C
Scientific reports 2018; 8: 15472 (IGR: 20-1)

78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Cioffi GA
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)

78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Birdsong OC
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)

79141 Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
Miyata K
Japanese Journal of Ophthalmology 2019; 63: 40-45 (IGR: 20-1)

78351 Glaucoma Drugs in the Pipeline
Rasmussen CA
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 345-351 (IGR: 20-1)

79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Kimball E
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)

78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Goldberg I
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)

79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Kimball E
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)

78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Ronquillo YC
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)

79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Krishnadas S; Gabelt BAT
Scientific reports 2018; 8: 15472 (IGR: 20-1)

79141 Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
Aihara M
Japanese Journal of Ophthalmology 2019; 63: 40-45 (IGR: 20-1)

78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Hofstedt D
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)

79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Pease ME
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)

78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Brandt JD
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)

79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Schaub J
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)

79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Kaufman PL
Scientific reports 2018; 8: 15472 (IGR: 20-1)

78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Johnson CA
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)

78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Shah TJ
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)

79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Schaub J
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)

78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Zangwill LM
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)

79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Quigley H
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)

79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Muthukkaruppan V
Scientific reports 2018; 8: 15472 (IGR: 20-1)

78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Gomez AT; Hoopes PCS
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)

78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Schneider S; Badger H; Bejanian M
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)

78256 Old and New Drug Classes Expanding To Include Glaucoma Treatments
Kish T
P and T 2018; 43: 489-502 (IGR: 19-4)

78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Iwamura R
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)

78148 Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision
Sharif NA
Neural Regeneration Research 2018; 13: 1145-1150 (IGR: 19-4)

78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Fuwa M
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)

78116 Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Tanna AP
Ophthalmology 2018; 125: 1741-1756 (IGR: 19-4)

78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Jacob TF
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)

78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Iwamura R
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)

78293 Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension
Kopczynski CC
Drugs of Today 2018; 54: 467-478 (IGR: 19-4)

78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Mahalingam K; Chaurasia AK
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)

78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Tanaka M
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)

78293 Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension
Heah T
Drugs of Today 2018; 54: 467-478 (IGR: 19-4)

78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Toris CB
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)

78116 Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Johnson M
Ophthalmology 2018; 125: 1741-1756 (IGR: 19-4)

78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Singh V
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)

78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Okanari E
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)

78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Dixit M
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)

78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Gowtham L
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)

78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Fan S; Taniguchi T
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)

78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Gupta S
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)

78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Ginsburg-Shmuel T
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)

78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Kirihara T
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)

78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Fonseca B
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)

78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Somarajan BI
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)

78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Odani-Kawabata N
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)

78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Ichikawa M
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)

78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Velpandian T
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)

78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Pintor J
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)

78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Shams N
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)

78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Odani-Kawabata N
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)

78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Yoneda K
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)

78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Sihota R
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)

78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Iwamura R
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)

78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Youdim MBH
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)

78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Iwamura R
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)

78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Major DT
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)

78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Yoneda K
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)

78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Gupta V
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)

78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Weinreb O
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)

78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Matsugi T; Shams NK
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)

78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Fischer B
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)

78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Zhang JZ
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)

76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Stack T
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)

76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Gu L
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)

77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Miller S
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)

76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Zhang QL
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)

77175 Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil
Inoue K
Japanese Journal of Ophthalmology 2018; 62: 508-516 (IGR: 19-3)

77101 Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
Hoy SM
Drugs 2018; 78: 773-780 (IGR: 19-3)

76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Hampel U
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)

76503 Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma
Honjo M
Japanese Journal of Ophthalmology 2018; 62: 109-126 (IGR: 19-3)

76816 Neuroprotective Effects of Psalmotoxin-1, an Acid-Sensing Ion Channel (ASIC) Inhibitor, in Ischemia Reperfusion in Mouse Eyes
Dibas A
Current Eye Research 2018; 43: 921-933 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Stacy R
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Kazemi A
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)

76551 Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma
Kusuhara S
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 809-814 (IGR: 19-3)

77039 The nitric oxide-guanylate cyclase pathway and glaucoma
Wareham LK
Nitric oxide : biology and chemistry 2018; 77: 75-87 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Prasanna G
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Stacy R
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Impagnatiello F
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)

76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Träger K
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)

76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Kwong JMK
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)

76503 Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma
Tanihara H
Japanese Journal of Ophthalmology 2018; 62: 109-126 (IGR: 19-3)

76551 Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma
Katsuyama A
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 809-814 (IGR: 19-3)

76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
McLaren JW
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Huttner K
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Vahabikashi A
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)

76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Bastia E
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)

76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Wang W
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)

77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Kulkarni S
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)

77175 Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil
Ishida K
Japanese Journal of Ophthalmology 2018; 62: 508-516 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ferrara L
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

77039 The nitric oxide-guanylate cyclase pathway and glaucoma
Buys ES
Nitric oxide : biology and chemistry 2018; 77: 75-87 (IGR: 19-3)

76816 Neuroprotective Effects of Psalmotoxin-1, an Acid-Sensing Ion Channel (ASIC) Inhibitor, in Ischemia Reperfusion in Mouse Eyes
Millar C
Current Eye Research 2018; 43: 921-933 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Watts J
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Almirante N
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)

76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Jiang Y
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)

76551 Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma
Matsumiya W
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 809-814 (IGR: 19-3)

77039 The nitric oxide-guanylate cyclase pathway and glaucoma
Sappington RM
Nitric oxide : biology and chemistry 2018; 77: 75-87 (IGR: 19-3)

76816 Neuroprotective Effects of Psalmotoxin-1, an Acid-Sensing Ion Channel (ASIC) Inhibitor, in Ischemia Reperfusion in Mouse Eyes
Al-Farra A
Current Eye Research 2018; 43: 921-933 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Adams C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Liu H
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)

77175 Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil
Tomita G
Japanese Journal of Ophthalmology 2018; 62: 508-516 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Adams C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Yadegari D
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)

76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Johnson M
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)

76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Kopczynski CC
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)

77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Ciesielski A
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ehara T
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
A-Tuya
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)

76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Scott E
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)

76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Brambilla S
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)

76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Heah TG
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)

77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Nikas SP
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Peace J
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76816 Neuroprotective Effects of Psalmotoxin-1, an Acid-Sensing Ion Channel (ASIC) Inhibitor, in Ischemia Reperfusion in Mouse Eyes
Yorio T
Current Eye Research 2018; 43: 921-933 (IGR: 19-3)

76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Yu F
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)

76551 Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma
Nakamura M
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 809-814 (IGR: 19-3)

76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Teister J
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Li B
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Novack GD
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)

77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Mackie K
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)

76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Grus F
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Wirta D
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Caprioli J
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)

76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Duquesroix B
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)

76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Dongmei
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)

76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Piri N
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Yang L
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Kothe AC
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)

76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Li LL
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)

77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Makriyannis A
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)

76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Prokosch-Willing V
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)

76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Sit AJ
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Walters T
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Bergamini MVW
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Xiang C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Lu ZJ
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Sall K
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Straiker A
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Seaman J
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Chang H
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ng CTH
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Ni X
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Kim S
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Zhang TZ
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Prasanna G
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Towler C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Mogi M
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Topley T
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Adams C
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
McAllister C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Adams C
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ghosh M
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Yan JH
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Newton R
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Wald M
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Newton R; Stacy R; Stacy R
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
He Y; Newton R
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Rice DS
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Newton R
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Mogi M
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)

77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Kolega R; Grosskreutz C
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)

75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Weinreb RN
Journal of Glaucoma 2018; 27: 7-15 (IGR: 19-2)

75286 Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits
Loma P
Journal of optometry 2018; 11: 69-74 (IGR: 19-2)

75045 Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
Williams PA
Journal of Glaucoma 2017; 26: 1161-1168 (IGR: 19-2)

75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Serle JB
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)

75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Kim J
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)

75170 Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules
Yu AK
Human Molecular Genetics 2017; 26: 4929-4936 (IGR: 19-2)

75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Pfeiffer N
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)

75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Giannaccini M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)

75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Voykov B
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)

75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Liebmann JM
Journal of Glaucoma 2018; 27: 7-15 (IGR: 19-2)

75286 Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits
Guzman-Aranguez A
Journal of optometry 2018; 11: 69-74 (IGR: 19-2)

75045 Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
Harder JM
Journal of Glaucoma 2017; 26: 1161-1168 (IGR: 19-2)

75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Usai A
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)

75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Katz LJ
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)

75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Kudisch M
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)

75170 Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules
Datta S
Human Molecular Genetics 2017; 26: 4929-4936 (IGR: 19-2)

75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Renieri G
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)

75286 Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits
de Lara MJP
Journal of optometry 2018; 11: 69-74 (IGR: 19-2)

75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
da Silva NRK
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)

75170 Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules
McMackin MZ
Human Molecular Genetics 2017; 26: 4929-4936 (IGR: 19-2)

75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Chiellini F
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)

75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Martin KR
Journal of Glaucoma 2018; 27: 7-15 (IGR: 19-2)

75045 Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
John SWM
Journal of Glaucoma 2017; 26: 1161-1168 (IGR: 19-2)

75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
McLaurin E
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)

75170 Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules
Cortopassi GA
Human Molecular Genetics 2017; 26: 4929-4936 (IGR: 19-2)

75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Guadagni V
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)

75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Kaufman PL
Journal of Glaucoma 2018; 27: 7-15 (IGR: 19-2)

75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Heah T
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)

75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Asada H
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)

75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Bell K
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)

75286 Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits
Pintor J
Journal of optometry 2018; 11: 69-74 (IGR: 19-2)

75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Ramirez-Davis N
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)

75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Aya-Shibuya E
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)

75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Richter P
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)

75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Andreazzoli M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)

75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Vittitow JL
Journal of Glaucoma 2018; 27: 7-15 (IGR: 19-2)

75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Bloomer MM
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)

75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Ori M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)

75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Weigel M
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)

75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Usner DW; Novack GD
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)

75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Pasqualetti M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)

75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Mudumba S
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)

75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Thieme H
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)

75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Kopczynski CC
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)

75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Wilhelm B
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)

75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Bhisitkul RB
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)

75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Dente L
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)

75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Desai TA
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)

75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Lorenz K
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)

75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)

American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)

75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Raffa V
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)

75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Feindor M; Wosikowski K; Janicot M; Päckert D; Römmich R; Mala C; Fettes P; Leo E
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)

74543 Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo
Liu H
Investigative Ophthalmology and Visual Science 2017; 58: 5129-5141 (IGR: 19-1)